Production (Stage)
EyePoint Pharmaceuticals, Inc.
EYPT
$9.03
$0.171.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.04M | 43.27M | 45.71M | 50.39M | 50.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.04M | 43.27M | 45.71M | 50.39M | 50.02M |
| Cost of Revenue | 161.66M | 133.85M | 109.28M | 98.24M | 84.77M |
| Gross Profit | -105.61M | -90.58M | -63.57M | -47.85M | -34.75M |
| SG&A Expenses | 55.76M | 55.28M | 53.40M | 50.77M | 52.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 217.41M | 189.13M | 162.68M | 149.01M | 136.85M |
| Operating Income | -161.37M | -145.85M | -116.97M | -98.62M | -86.83M |
| Income Before Tax | -146.69M | -130.78M | -103.49M | -86.74M | -78.83M |
| Income Tax Expenses | 90.00K | 90.00K | 83.00K | 83.00K | 83.00K |
| Earnings from Continuing Operations | -146.78 | -130.87 | -103.57 | -86.82 | -78.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -146.78M | -130.87M | -103.57M | -86.82M | -78.92M |
| EBIT | -161.37M | -145.85M | -116.97M | -98.62M | -86.83M |
| EBITDA | -159.64M | -144.31M | -115.78M | -97.73M | -86.17M |
| EPS Basic | -2.41 | -2.31 | -2.01 | -1.80 | -1.83 |
| Normalized Basic EPS | -1.50 | -1.44 | -1.25 | -1.12 | -1.12 |
| EPS Diluted | -2.41 | -2.31 | -2.01 | -1.80 | -1.83 |
| Normalized Diluted EPS | -1.50 | -1.44 | -1.25 | -1.12 | -1.12 |
| Average Basic Shares Outstanding | 241.98M | 225.12M | 202.74M | 186.63M | 171.00M |
| Average Diluted Shares Outstanding | 241.98M | 225.12M | 202.74M | 186.63M | 171.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |